We tested this hypothesis by staining the tumor vasculature with an endothelial marker (Meca-32) and a mature pericyte marker (Desmin) to determine the relative pericytic coverage of the tumor vasculature comparing control tumors, erlotinib-treated tumors, and Hb-egf mutant tumors. Here, DES is linked to neoplasm.